National Comprehensive Cancer Network (NCCN). Non-small cell lung cancer (Version 7.2021). 2021. Accessed November 9, 2021. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
Kalemkerian GP, et al. Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol. 2018;36:911-919.
Planchard D, et al; ESMO Guidelines Committee. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv192-iv237.
Yang H, et al. New horizons in KRAS-mutant lung cancer: dawn after darkness. Front Oncol. 2019;9:953.
Araujo LH, et al. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer. BMC Cancer. 2021;21:193.
Veluswamy R, et al. KRAS G12C-mutant non-small cell lung cancer: biology, developmental therapeutics, and molecular testing. J Mol Diagn. 2021;23:507-520.
Lanman BA, et al. Discovery of a covalent inhibitor of KRAS G12C (AMG 510) for the treatment of solid tumors. J Med Chem. 2020;63:52-65.
Biernacka A, et al. The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma. Cancer Genet. 2016;209:195-198.
Slebos RJ, et al. Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst. 1991;83:1024-1027.
Dearden S, et al. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013;24:2371-2376.
Eberhard DA, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005;23:5900-5909.
Miller VA, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol. 2008;26:1472-1478.
Mitsudomi T, et al. Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res. 1991;51:4999-5002.
Scheffler M, et al. K-ras mutation subtypes in NSCLC and associated co-occuring mutations in other oncogenic pathways. J Thorac Oncol. 2019;14:606-616.
Skoulidis F, et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 2015;5:860-877.
Skoulidis F, et al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 2018;8:822-835.
Arbour KC, et al. Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer. Clin Cancer Res. 2018;24:334-340.
Launonen V. Mutations in the human LKB1/STK11 gene. Hum Mutat. 2005;26:291-297.
Cemiplimab [prescribing information]. Approved 2018.
Sotorasib [prescribing information]. Approved 2021.
Gandhi L, et al; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078-2092.
Rodríguez-Abreu D, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol. 2021;32:881-895.
Socinski MA, et al; IMpower150 Study Group. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288-2301.
Socinski MA, et al. IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC. J Thorac Oncol. 2021;16:1909-1924.
West H, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:924-937.
Paz-Ares L, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:198-211.
Hellmann MD, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378:2093-2104.
Hellmann MD, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381:2020-2031.
Paz-Ares LG, et al. First-line nivolumab plus ipilimumab in advanced non-small cell lung cancer: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial. J Thorac Oncol. 2021. doi:10.1016/j.jtho.2021.09.010 [Epub ahead of print]
Mok TSK, et al; KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819-1830.
Pembrolizumab [prescribing information]. Approved 2014.
Canon J, et al. The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575:217-223.
US Food and Drug Administration. FDA grants accelerated approval to sotorasib for KRAS G12C mutated NSCLC. May 28, 2021. Accessed September 28, 2021. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sotorasib-kras-g12c-mutated-nsclc
ClinicalTrials.gov. Study to compare AMG 510 "proposed INN sotorasib" with docetaxel in non small cell lung cancer (NSCLC) (CodeBreak 200). NCT04303780. Updated September 23, 2021. Accessed September 28, 2021. https://clinicaltrials.gov/ct2/show/NCT04303780
ClinicalTrials.gov. A Phase 1/2 Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in subjects with Solid Tumors with a Specific KRAS Mutation (CodeBreak100). NCT03600883. Updated November 4, 2021. Accessed November 9, 2021. https://clinicaltrials.gov/ct2/show/NCT03600883
Hong DS, et al. KRAS^G12C inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383:1207-1217.
Skoulidis F, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384:2371-2381.
Hallin J, et al. The KRAS^G12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 2020;10:54-71.
Janne PA. KRYSTAL-1: updated safety and efficacy data with adagrasib (MRTX849) in NSCLC with KRASG12C mutation from a phase I/II study. Presented at: 30th EORTC-NCI-AACR virtual Symposium; November 13-16, 2020; Dublin, Ireland.
Reck M, et al. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol. 2021;32:1101-1110.
Riely G, et al. KRYSTAL-1: activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non-small-cell lung cancer (NSCLC) harboring KRASG12C mutation. J Thor Oncol. 2021;16(suppl_4):S748-S802.
ClinicalTrials.gov. Phase 3 study of MRTX849 vs docetaxel in patients with advanced non-small cell lung cancer with KRAS G12C mutation (KRYSTAL-12). NCT04685135. Updated August 17, 2021. Accessed September 28, 2021. https://clinicaltrials.gov/ct2/show/NCT04685135

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Ferdinandos Skoulidis, MD, PhD

Assistant Professor
Department of Thoracic/Head and Neck Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Disclosures

Disclosure: Ferdinandos Skoulidis, MD, PhD, has the following relevant financial relationships:
Advisor or consultant for: Amgen Inc.; Beigene; Intellisphere LLC; Navire Pharma
Speaker or a member of a speakers bureau for: Bristol Myers Squibb; RV Mais Promocao Eventos LTDS
Grants for clinical research from: Amgen Inc.; Boehringer Ingelheim; Merck & Co; Mirati Therapeutics; Novartis; Pfizer
Stocks, stock options, or bonds from: BioNTech SE; Moderna Inc.
Ownership of an ineligible company: BioNTech SE; Moderna Inc.
Other: Travel expenses for Tango Therapeutics; Food and Beverage Expenses for Amgen Inc. and AstraZeneca Pharmaceuticals

Editor

Lisa Cockrell, PhD

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Lisa Cockrell, PhD, has disclosed no relevant financial relationships.

Amy Furedy, RN, OCN

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Amy Furedy, RN, OCN, has disclosed no relevant financial relationships.

CME Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

None of the nonfaculty planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME / ABIM MOC

Effectively Managing KRAS-Mutated Non-Small Cell Lung Cancer: Translating Evidence Into Practice

Authors: Ferdinandos Skoulidis, MD, PhD
CME / ABIM MOC Released: 12/13/2021
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 12/13/2022, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for oncologists, pulmonologists, and pathologists.

The goal of this activity is to improve clinicians' skill in using precision medicine approaches to manage patients with KRAS-mutated non-small cell lung cancer (NSCLC).

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Clinical trial data on targeted therapies being evaluated to manage patients with KRAS-mutated NSCLC
Have greater competence related to
- Identifying which molecular tests to administer to guide treatment for KRAS-mutated NSCLC
- Selecting treatment guided by molecular test results in a patient with KRAS-mutated NSCLC
- Managing treatment-related adverse events in patients receiving targeted therapy for KRAS-mutated NSCLC

Disclosures

Faculty

Ferdinandos Skoulidis, MD, PhD

Assistant Professor
Department of Thoracic/Head and Neck Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Disclosures

Disclosure: Ferdinandos Skoulidis, MD, PhD, has the following relevant financial relationships:
Advisor or consultant for: Amgen Inc.; Beigene; Intellisphere LLC; Navire Pharma
Speaker or a member of a speakers bureau for: Bristol Myers Squibb; RV Mais Promocao Eventos LTDS
Grants for clinical research from: Amgen Inc.; Boehringer Ingelheim; Merck & Co; Mirati Therapeutics; Novartis; Pfizer
Stocks, stock options, or bonds from: BioNTech SE; Moderna Inc.
Ownership of an ineligible company: BioNTech SE; Moderna Inc.
Other: Travel expenses for Tango Therapeutics; Food and Beverage Expenses for Amgen Inc. and AstraZeneca Pharmaceuticals

Editor

Lisa Cockrell, PhD

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Lisa Cockrell, PhD, has disclosed no relevant financial relationships.

Amy Furedy, RN, OCN

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Amy Furedy, RN, OCN, has disclosed no relevant financial relationships.

CME Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC

Effectively Managing KRAS-Mutated Non-Small Cell Lung Cancer: Translating Evidence Into Practice

Authors: Ferdinandos Skoulidis, MD, PhDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 12/13/2021

Valid for credit through: 12/13/2022, 11:59 PM EST

processing....

The following cases are modeled on the interactive grand rounds approach. The questions within the activity are designed to test your current knowledge. After each question, you will be able to see whether you answered correctly and read evidence-based information that supports the most appropriate answer choice. The questions are designed to challenge you; you will not be penalized for answering the questions incorrectly. At the end of the activity, there will be a short post-test assessment based on the material presented.

CASE 1: PATIENT HISTORY AND PRESENTATION

A 56-year-old white woman presented to her primary care provider with a 3-month history of cough. At presentation, she also stated that she had been experiencing increasing fatigue that was abnormal for her. She was a former smoker, having quit smoking 5 years earlier. She was otherwise very healthy, was not on any medications, and maintained a busy life and career. Given her prior smoking history, her physician ordered a chest x-ray, which revealed a small mass in her left lung. Following referral, a bronchoscopy with biopsy confirmed non-small cell lung cancer (NSCLC) with adenocarcinoma histology. An abdominal computed tomography (CT) scan showed a liver lesion, and brain metastasis was found on conventional magnetic resonance imaging (MRI). Subsequent positron emission tomography (PET)/CT revealed multiple involved lymph nodes in her abdomen.

Page 1 of 12

CME / ABIM MOC Information

Print
Like Tweet

References

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Ferdinandos Skoulidis, MD, PhD

Editor

Lisa Cockrell, PhD

Amy Furedy, RN, OCN

CME Reviewer

Robert Morris, PharmD

Peer Reviewer

CME / ABIM MOC

Effectively Managing KRAS-Mutated Non-Small Cell Lung Cancer: Translating Evidence Into Practice

Target Audience and Goal Statement

Disclosures

Faculty

Ferdinandos Skoulidis, MD, PhD

Editor

Lisa Cockrell, PhD

Amy Furedy, RN, OCN

CME Reviewer

Robert Morris, PharmD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Effectively Managing KRAS-Mutated Non-Small Cell Lung Cancer: Translating Evidence Into Practice

CASE 1: PATIENT HISTORY AND PRESENTATION